Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Antifungal agents with enhanced activity in acidic ph

A fungal infection and mold technology, applied in the direction of antifungal agents, organic active ingredients, medical preparations containing active ingredients, etc., can solve the problems of anti-candida antifungal performance reduction and other problems

Pending Publication Date: 2020-05-01
SCYNEXIS INC
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At the same time, however, previous studies have demonstrated a substantial reduction in the antifungal properties of various agents against Candida in acidic pH environments, and more specifically in pH environments similar to the vaginal environment, which has a pH of about 4 to 4.5

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Antifungal agents with enhanced activity in acidic ph
  • Antifungal agents with enhanced activity in acidic ph
  • Antifungal agents with enhanced activity in acidic ph

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0125] Evaluation of the effect of pH on the susceptibility of clinical vaginal Candida glabrata and Candida albicans isolates

[0126] The purpose of this study was to determine whether changes in the pH of the test medium were beneficial to representative compounds of Candida glabrata and Candida albicans vaginal isolates to enfufungin derivatives using fluconazole and micafungin as comparators (e.g. Citrate of SCY-078) has an effect on the in vitro susceptibility.

[0127] Materials and methods

[0128] Clinical isolates and antifungal agents

[0129] Ten strains each of C. glabrata and C. albicans vaginal isolates were tested. Strains were obtained from recent clinical trial patients with vulvovaginal candidiasis (VVC) prior to treatment. Candida strains were obtained from the Mycology Reference Library (MRL) at Case Western Reserve University School of Medicine, Ohio, USA.

[0130] Antifungal Susceptibility Testing

[0131] Susceptibility testing was performed us...

example 2

[0175] Vaginal concentrations of SCY-078 after oral administration to mice

[0176] The goal of this study was to determine the exposure of SCY-078 in vaginal tissue and secretions after oral administration of SCY-078 to mice and the relationship between this exposure and the concentration of SCY-078 in plasma, that is, the experimental parameters of Candida infection. Identify the model.

[0177] method

[0178] Female CD-1 mice were administered SCY-078 by oral gavage (n=3 / time point / dose group) for one, two or eight doses ranging from 10 to 80 mg / kg QD (once daily ) and BID (twice daily) dosage regimen with and without the following starting doses:

[0179] QD (Day 1): 10, 20, 40, 80mg / kg

[0180] BID (Day 1): 10 / 5, 20 / 10, 40 / 20, 80 / 40mg / kg

[0181] BID repeat dose (Day 1 to Day 4): 10 / 5, 20 / 10 40 / 20, 80 / 40 mg / kg on Day 1; 5, 20, 20, 40mg / kg BID

[0182] Blood, vulvovaginal tissue, and vaginal secretions were collected prior to dosing and at 1, 2, 4, 6, 8, 12, 18, and...

example 3

[0191] A Phase 2 Study of SCY-078 in Moderate and Severe Vulvovaginal Candidiasis (VVC)

[0192] This study is a proof-of-concept study designed to evaluate the safety and efficacy of two dosing regimens of oral SCY-078 (administered as phosphate) in individuals presenting with moderate to severe VVC.

[0193] method

[0194] Key selection criteria include:

[0195] 1. Individuals with moderate to severe VVC as determined from a vaginal discharge sample by a positive potassium hydroxide (KOH) test

[0196] 2. Three episodes of vaginitis in the last year determined to be caused by Candida or responding to antifungal therapy

[0197] Subjects were randomized in a 1:1:1 ratio to one of three treatment groups: oral SCY-078 at a starting dose of 1250 mg SCY-078 followed by 750 mg SCY-078 QD for 2 or 4 days, or oral fluoride Conazole 150mg for 1 day.

[0198] Subjects were assessed on Day 24 (Test of Cure Visit), Day 60, Day 90, and Day 120 (End of Study).

[0199] Analysis inclu...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Enfumafungin derivative triterpenoid antifungal compounds are used to treat or prevent fungal infections occurring in or under acidic conditions where the pH is lower than about 7, due to their unexpected, enhanced efficacy under such conditions. The enfumafungin derivative triterpenoids (or pharmaceutically acceptable salts or hydrates thereof) are inhibitors of (1,3)-beta- D-glucan synthesis andare useful in the treatment or prevention of yeast or mold infections that occur in anatomic areas having a low pH, such as the vaginal cavity, or under acidic local environment conditions such of those seen in fungal abscesses, empyema, or upper gastrointestinal tract infections.

Description

technical field [0001] The present invention relates to the use of enfumafungin derivative triterpenoid antifungal compounds for the treatment or prevention of fungal infections occurring in or under acidic conditions with a pH below about 7. More specifically, the present invention relates to derivative triterpenoids (or pharmaceutically acceptable salts or hydrates thereof) as inhibitors of (1,3)-β-D-glucan synthesis in the treatment or prevention of Yeast or mold infections that occur in conditions with a low acidic pH or in anatomical areas; such infections include vaginal yeast infections where the pH is usually about 4 to about 4.5, abscesses where the pH is usually about 5.5 to about 6.8, and upper gastrointestinal tract infection. Antifungal agents exhibiting enhanced antifungal properties at acidic pH are expected to offer advantages in the treatment of fungal infections that occur at low pH conditions, such as vulvovaginal candidiasis (VVC), abscesses, and upper gas...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/4196A61K31/4439A61P31/10A61P15/02
CPCA61K31/4196A61K31/4439A61P15/02A61P31/10A61K9/0014A61K9/0053A61K31/4409
Inventor D·A·安古洛·冈萨雷斯
Owner SCYNEXIS INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com